A Phase 4 interventional study of Doxazosin (drug) in Hypertension, sponsored by Japan Heart Foundation. Completed at 1 site in Japan. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2006-02-02.
Sponsored by Japan Heart Foundation · Phase 4, Interventional, and Treatment
The purpose of this study is to examine whether strict blood pressure (BP) control by doxazosin using home BP monitoring, especially targeting the morning BP level, can reduce hypertensive target organ damage.
Morning blood pressure may play an important role in the pathogenesis of hypertensive target organ damage. Increased sympathetic nerve activity is reported to be one of the mechanisms of morning hypertension; however, there are no available data that show whether strict home blood pressure control, especially in the morning period, can reduce target organ damage.We will evaluate whether strict morning blood pressure control by sympathetic nervous system blockade using an alfa-blocker, doxazosin, and with the addition of a beta-blocker if needed, can reduce hypertensive target organ damage.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 600 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →This is the only study on the registry with Japan Heart Foundation as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
brain natriuretic peptide and the urinary albumin excretion/creatinine ratio at 6 months
This study is completed, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.